Immunotherapy for Infectious Diseases

272 Sili, Heslop, and Rooney
32. Barry MA, Johnston SA. Biological features of genetic immunization. Vaccine 1997;
15:788–791.
33. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4� T cell responses: the alternative
approaches. Annu Rev Immunol, 1997; 15:297–322.
34. Chow YH, Chiang BL, Lee YL, et al. Development of Th1 and Th2 populations and the
nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery
of various cytokine genes. J Immunol 1998; 160:1320–1329.
35. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Improved efficacy of dendritic cell vaccines
and successful immunization with tumor antigen peptide-pulsed peripheral blood
mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer
1999; 80:324–333.
36. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral
immune responses to hepatitis C virus core protein using DNA-based vaccines augmented
with cytokine-expressing plasmids. J Immunol 1997; 158:1231–1237.
37. Kim JJ, Nottingham LK, Tsai A, et al. Antigen-specific humoral and cellular immune
responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or
IL-18 gene adjuvants. J Med Primatol 1999; 28:214–223.
38. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-gamma
production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol
1996; 167:72–78.
39. Sato Y, Roman M, Tighe H, et al. Immunostimulatory DNA sequences necessary for effective
intradermal gene immunization. Science 1996; 273:352–354.
40. Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor
immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996;
156:2369–2375.
41. Lin KY, Guarnieri FG, Staveley-O’Carroll KF, et al. Treatment of established tumors with
a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.
Cancer Res 1996; 56:21–26.
42. Wu TC, Guarnieri FG, Staveley-O’Carroll KF, et al. Engineering an intracellular pathway
for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci
USA 1995; 92:11671–11675.
43. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide-mediated immunization therapy of
cancer. Semin Oncol 1996; 23:135–147.
44. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ. Potential DNA vaccine integration into
host cell genome. Ann NY Acad Sci 1995; 772:30–39.
45. Suhrbier A. Multi-epitope DNA vaccines. Immunol Cell Biol 1997; 75:402–408.
46. Thomson SA, Sherritt MA, Medveczky J, et al. Delivery of multiple CD8 cytotoxic T cell
epitopes by DNA vaccination. J Immunol 1998; 160:1717–1723.
47. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;
392:245–252.
48. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev
Med 1999; 50:507–529.
49. De Bruijn ML, Schuurhuis DH, Vierboom MP, et al. Immunization with human papillomavirus
type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant
induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res
1998; 58:724–731.
50. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using
autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52–58.
51. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers
for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a
human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol
1995; 18:86–94.